1. Matsui M, Yamadera M, Saito T, Fujimura H, Sakoda S, Koga Y. Biomarker changes associated with clinical symptoms in MELAS patient. Neurol Clin Neurosci. 2019, 00:1-3, doi: 10.1111/ncn3.12325
2. Kagiyama Y, Yatsuga S, Kinoshita M, Koteda Y, Kishimoto S, Koga Y, Suda K. Growth Differentiation Factor 15 as a useful biomarker of heart failure in young patients with unrepaired congenital heart disease of left to right shunt. J Cardiol. 2020, 75(6):697-701, doi: 10.1016/j.jjcc.2019.12.008
3. Nohara S, Ishii A, Yamamoto F, Yanagiha K, Moriyama T, Tozaka N, Miyake Z, Yatsuga S, Koga Y, Hosaka T, Terada M, Yamaguchi T, Aizawa S, Mamada N, Tsuji H, Tomidokoro Y, Nakamagoe K, Ishii K, Watanabe M, Tamaoka A. GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis. Journal of the neurological sciences. 2019, 405:116429, doi: 10.1016/j.jns.2019.116429
4. Ikawa M, Povalko N, Koga Y. Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Current opinion in clinical nutrition and metabolic care, 2020, 23(1):17-22, doi: 10.1097/MCO.0000000000000610
5. Kadoya T, Sakakibara A, Kitayama K, Yamada Y, Higuchi S, Kawakita R, Kawasaki Y, Fujino M, Murakami Y, Shimura M, Murayama K, Ohtake A, Okazaki Y, Koga Y, Yorifuji T. Successful treatment of infantile-onset ACAD9-related cardiomyopathy with a combination of sodium pyruvate, beta-blocker, and coenzyme Q10. J Pediatr Endocrinol Metab. 2019, 32(10):1181-1185. doi: 10.1515/jpem-2019-0205
6. Murayama K, Shimura M, Liu Z, Okazaki Y, Ohtake A Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases. J Hum Genet. 2019, 64(2):113-125, doi: 10.1038/s10038-018-0528-6
7. 古賀靖敏. ミトコンドリア病の治療薬および疾患バイオマーカーの開発. 日本小児科学会雑誌. 2019, 123(4):686-97
8. 古賀靖敏. ミトコンドリア病のバイオマーカーGDF15. 実験科学 増刊号 ミトコンドリアと疾患・老化. 2019, 37(12):174-81
9. 井川正道, 岡沢秀彦, 米田誠. 酸化ストレスイメージング:ミトコンドリア病,神経変性疾患への応用. BRAIN and NERVE. 2019, 71(2):161-166
10. 井川正道, 米田誠. 脳神経疾患のPET酸化ストレスイメージング. 実験医学. 2019, 37(12):2060-2066